“[W]hat will the day be like when we finally defeat AIDS, tuberculosis and malaria?” Arianna Huffington, president and editor-in-chief of the Huffington Post Media Group, asks in the Huffington Post’s “The Big Push” blog. “[W]ith the launch today of The Big Push campaign — co-sponsored by the Global Fund [to Fight AIDS, Tuberculosis and Malaria] and the Huffington Post — this might be more than a thought exercise … because the progress that’s been made against these diseases in only the last 10 years has been so staggering that we may actually be in sight of the day when no child is born with HIV, nobody dies of malaria and we stop the spread of tuberculosis,” she continues and provides some statistics.
“Over the next few weeks, appropriators will be engaged in the challenging task of evaluating U.S. foreign assistance funding, including how effectively Congress’ global health investments are being used,” Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation; Molly Joel Coye, interim president and CEO of PATH; Carolyn Miles, president and CEO of Save the Children; and Richard Stearns, president of World Vision, write in this Roll Call opinion piece. They continue, “As organizations funded in part by the U.S. government to implement global health programs in the field,” we “see firsthand how U.S. global health programs are working, and why now is not the time to cut multilateral and bilateral funding for these efforts.”
“Afghanistan has begun work on a $30 million hospital for the treatment of tuberculosis [TB], a disease that health officials say kills more than 10,000 Afghans every year,” VOA’s “Breaking News” blog reports. “The Japanese government is paying for the 80-bed center in the Afghan capital, which will also treat malaria and AIDS patients,” the news service writes, noting, “Japan is the second-largest donor to Afghanistan, after the United States.” VOA adds, “During Thursday’s groundbreaking in Kabul, Afghan Health Minister Suraya Dalil said Afghanistan ranks in the top 20 worldwide for the most TB patients,” and she noted the country has 2,000 centers nationwide that can diagnose and treat the disease (5/17).
U.S. Ambassador to Nigeria Terence McCulley on Tuesday in Abuja, Nigeria, launched a five-year, $224 million USAID program, titled Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS), that aims to “increas[e] access to high-quality comprehensive HIV/AIDS and tuberculosis prevention, treatment, care and related services through improved efficiencies in service delivery,” the Daily Trust reports (Odeyemi/Odafor, 5/8).
“The U.K. Department for International Development [DfID] is reviving its budget support to the Malawian government after rerouting aid to non-governmental organizations last year,” Devex reports. “Ten million pounds ($16 million) will go to the country’s health system, according to a [DfID] press release [.pdf] published Saturday,” Devex writes, noting, “This is part of the 110 million pounds [$140.7 million] DfID previously agreed to provide in support of Malawi’s Health Sector Strategic Plan, which runs 2011 to 2016” (5/14).
In a guest post on the Global Health Technologies Coalition’s “Breakthroughs” blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), “a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty.” Aeras, “a non-profit biotech focused on developing vaccines against TB,” has partnered with IDRI to develop a novel tuberculosis (TB) vaccine candidate, Rosen notes and summarizes Reed’s responses to questions regarding TB vaccine development (Taylor, 5/29).
“An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis [TB],” according to a study conducted by U.S. government and South Korean researchers and published in the New England Journal of Medicine on Wednesday, Reuters reports (Steenhuysen, 10/17). The “small study offers a bit of cautious optimism about the prospects for treatment of tuberculosis, … showing that adding a 12-year-old antibiotic called linezolid, brand name Zyvox, to existing treatments cured nearly 90 percent of patients with a form of tuberculosis resistant to both first- and second-line antibiotics,” NPR’s “Shots” blog writes (Knox, 10/18). “However, most of the patients [in the study] — 82 percent — experienced side effects while on the treatment, which tempered the findings, the team reported,” Reuters notes. “Researchers are desperately looking for new treatments for drug-resistant forms of TB, which threatens to derail progress in the global fight to eradicate the disease,” according to the news agency (10/17).
Number Of New TB Infections Fall, But Drug Resistance, Lack Of Funding Could Slow Progress, WHO Reports
“New tuberculosis [TB] infections dropped 2.2 percent worldwide last year, but with nearly nine million new infections, the World Health Organization said TB remains a massive problem that could worsen if countries shortchange funding to fight it,” Reuters reports (Steenhuysen, 10/17). “In a new report issued Wednesday, the U.N. agency estimated there were about 8.7 million new cases of TB last year, down from about 8.8 million in 2010,” and “[t]he number of deaths was unchanged at about 1.4 million — making it the second-leading killer among infectious diseases after AIDS,” the Associated Press writes (Cheng, 10/17). “The number of people becoming ill with tuberculosis has been falling steadily for roughly a decade after a surge in the 1990s,” but “those numbers are still huge, and only 19 percent of those infected with forms of the disease that are resistant to multiple tuberculosis drugs are being diagnosed, the WHO estimated,” according to the Wall Street Journal (McKay, 10/18). BBC News notes the report “warned of ‘persistently slow progress’ in treating tuberculosis which is resistant to antibiotics” (Gallagher, 10/17).
In a BMJ Group Blogs post, Caroline Robinson, global health advocacy manager for Results U.K., discusses the prevalence and treatment of tuberculosis (TB) and drug-resistant TB in Europe and provides the example of Romania. She writes, “[E]vidence brought to light in a new report [.pdf] released recently outlining the effect funding shortages will have on HIV and TB, including drug-resistant TB, in the European region suggests that Romania does not have the institutional capacity to ensure its citizens have the basic right to health. The country relies on grants from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which look set to end in 2013.” She continues, “[Global Fund] Board members should ensure that middle-income countries with epidemics among key populations can access critical Global Fund contributions and the E.U. and its member states must continue to provide the resources the fund requires to meet demand. Unless such support is given, countries like Romania will continue to fall further down the league tables in terms of treatment for this curable disease” (10/10).
Global Health Funding Cuts Threatening Fight Against HIV, TB In Eastern Europe, Central Asia, NGO Report Says
The fight against HIV and tuberculosis (TB) in Eastern Europe and Central Asia is being threatened by cuts in global health funding, according to “a report [.pdf] by leading European non-governmental health organizations,” Reuters reports. In the report, “experts called on the European Union to step in to fill the gaps left by global donors to countries within and neighboring its borders,” the news service notes. According to Reuters, “[c]ountries in Eastern Europe and Central Asia have some of the world’s fastest growing HIV epidemics,” and “Europe is also home to the world’s highest documented rates of drug-resistant TB” (Kelland, 9/18).